Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Olympus Biotech
Olympus Biotech
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Opgenra
Eptotermin alfa
2009-02-19
Spondylolisthesis
,
Tibial fractures
Osigraft
Eptotermin alfa
2001-05-17
Spondylolisthesis
,
Tibial fractures
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Eptotermin alfa
spondylolisthesis
,
intervertebral disc degeneration
Trafermin
periodontitis
,
diabetic foot
,
ulcer
,
foot ulcer
,
tympanic membrane perforation
,
alveolar bone loss
,
periodontal attachment loss
Aspartame
neoplasms
,
melanoma
,
overweight
,
weight loss
,
nutrition disorders
,
hemophilia b
,
sickle cell anemia
,
thalassemia
,
type 2 diabetes mellitus
,
obesity
,
diabetes mellitus
,
type 1 diabetes mellitus
,
transient ischemic attack
,
hypoxia
,
diabetic neuropathies
,
nephritis
,
knee osteoarthritis
,
osteoarthritis
,
diastolic heart failure
,
myocardial reperfusion
,
pituitary dwarfism
,
insulin resistance
,
chronic renal insufficiency
,
cardiovascular diseases
,
heart disease risk factors
,
endocrine system diseases
,
laron syndrome
,
growth disorders
,
latent autoimmune diabetes in adults
,
hemophilia a
,
dwarfism
,
dyslipidemias
,
heart failure
,
kidney diseases
,
inflammation
,
atherosclerosis
,
prediabetic state
Bevifimod
psoriatic arthritis
,
rheumatoid arthritis
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use